Although the exact mechanism how GLP-1 and GPR40 agonist improve neurodegeneration is still elusive, it appears that gut-restricted GPR40 agonist might have the potential for the treatment of neurodegenerative diseases, pending the clinical results of Semaglutide for Alzheimer’s disease. The gene discussed is FFAR1; the disease is early-onset autosomal dominant Alzheimer disease.